Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Emitasvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Emitasvir is a Chinese oral antiviral for adults whose hepatitis C virus is genotype 1 and whose liver has not yet developed cirrhosis. One 100 mg capsule is swallowed each day alongside sofosbuvir, and the pair is continued for 12 weeks. Its marketing licence in China is held by YiChang HEC ChangJiang Pharmaceutical Co., Ltd., part of the HEC (Dongyangguang) group, and Chinese news reports give its brand as 东卫恩 (Dongwei'en).
The National Medical Products Administration (NMPA) of China granted marketing approval in December 2020 as a Class 1 innovative chemical drug, under approval number 国药准字H20200015. The approved use is narrow and specific:
A liver specialist confirms the genotype and checks for scarring before deciding whether this course fits. Our hepatology medicines section lists the other imported liver treatments we help with.
The capsule contains emitasvir phosphate, an inhibitor of NS5A, a viral protein that hepatitis C relies on for replicating its RNA and packaging fresh copies of itself. Its partner works on NS5B, the polymerase enzyme, so each day the virus is hit at two separate steps of its life cycle. Hitting two targets together is what makes a short, all-oral course possible.
The registration study (NCT03487107) was a single-arm, open-label phase 3 trial at 36 hospitals in mainland China, published in the Journal of Clinical and Translational Hepatology in 2020. It enrolled 362 adults with genotype 1 infection and no cirrhosis (359 genotype 1b, 3 genotype 1a); about one in five had already been through interferon-based therapy.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Part of a two-drug course: this capsule only works with sofosbuvir, so the warnings in the sofosbuvir prescribing information cover the whole 12 weeks as well. Stopping one medicine means the other is stopped too.
Side effects in the phase 3 study (362 patients): any adverse event was recorded in 77.1%, most often upper respiratory infection (14.1%), high cholesterol (13.5%) and high triglycerides (9.7%). About one in three (35.6%) had an event judged related to treatment, mostly grade 1. Sixteen people (4.4%) had a serious event, none considered linked to the medicines. Nobody stopped or paused treatment because of side effects, and no deaths occurred.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Each import is made in the name of a single patient, applied for by that patient or the treating hospital, under the Indian rules for personal import of unregistered medicines. Keep these papers ready:
Only after the prescription and reports have been checked and any import permit required has come through.
No. CDSCO has not granted it marketing approval, so you will not find it at an Indian chemist. Neither the American FDA nor Europe's EMA has licensed it; China is the only country where it is registered.
Your specialist may ask for it under the Named Patient Program (NPP), the lawful path for importing an unregistered medicine for a single patient. The same HEC group also makes the newer pan-genotypic pairing of netanasvir and encofosbuvir tablets, which we can also arrange on prescription.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is a small-molecule capsule, and we keep and transport it following the storage line printed on the Chinese carton, unopened, using temperature-controlled shipping. At one capsule a day, a full course is 84 capsules; the number of boxes depends on the pack size supplied, which we confirm in the quote. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Being an oral capsule rather than a cold-chain injection, this medicine can be sent to most Indian cities once a liver specialist's prescription and the import papers are complete.
Liver hospitals in the capital treat many genotype 1 patients, and dispatch from our base in New Delhi means a short wait once papers are cleared.
A Mumbai hepatologist can email the genotype and FibroScan reports, and we confirm import needs for both medicines in the course.
Patients in Bangalore can choose home delivery or collection at the clinic that will run their week-4 and end-of-treatment tests.
Gastroenterology units in Chennai can fix a start date with us so all 84 capsules are in hand before day one.
For Hyderabad and the rest of Telangana, one complete shipment avoids breaks in the daily dose over 12 weeks.
Families in Kolkata and the eastern states receive a written estimate and expected arrival date before anything is booked.
Pune patients get a message at each step, from document check to customs clearance to final hand-over.
Doctors in Ahmedabad and across Gujarat can begin the request by sharing the prescription and recent HCV RNA result.
People in Jaipur and smaller Rajasthan towns can receive the capsules by courier and avoid a long trip for collection.
Treating doctors in Chandigarh, Mohali and the hill states can arrange for all 12 weeks of capsules to reach their clinic.
In Lucknow and across Uttar Pradesh, we work with the treating doctor so every document carries the patient's own name.
Patients in Kochi and elsewhere in Kerala can receive the sealed cartons at home after the prescription is verified.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 20 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message